Article
Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jan 2009
McKay James D, McCullough Marjorie L, Ziegler Regina G, Kraft Peter, Saltzman Barbara S, Riboli Elio, Barricarte Aurelio, Berg Christine D, Bergland Goran, Bingham Sheila, Brustad Magritt, Bueno-de-Mesquita H Bas, Burdette Laurie, Buring Julie, Calle Eugenia E, Chanock Stephen J, Clavel-Chapelon Françoise, Cox David G, Dossus Laure, Feigelson Heather Spencer, Haiman Christopher A, Hankinson Susan E, Hoover Robert N, Hunter David J, Husing Anika, Kaaks Rudolph, Kolonel Laurence N, Le Marchand Loic, Linseisen Jakob, McCarty Catherine A, Overvad Kim, Panico Salvatore, Purdue Mark P, Stram Daniel O, Stevens Victoria L, Trichopoulos Dimitrios, Willett Walter C, Yuenger Jeffrey, Thun Michael J
Abstract excerpt
BACKGROUND: Vitamin D is hypothesized to lower the risk of breast cancer by inhibiting cell proliferation via the nuclear vitamin D receptor (VDR). Two common single nucleotide polymorphisms (SNP) in the VDR gene (VDR), rs1544410 (BsmI), and rs2228570 (FokI), have been inconsistently associated with breast cancer risk. Increased risk has been reported for the FokI ff genotype, which encodes a less...
Read the complete abstract on PubMed